You just read:

Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Praluent® (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy

News provided by

Regeneron Pharmaceuticals, Inc.

23 Mar, 2016, 02:00 ET